Incyte equity research
WebApr 4, 2024 · Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE. Recommended Stories Get a free copy of the StockNews.com research report on Incyte (INCY) WebApr 11, 2024 · The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.50 and a current ratio of 3.54. ... On average, research analysts expect that Incyte will post 3.29 earnings per share for the ...
Incyte equity research
Did you know?
WebApr 15, 2024 · In other Incyte news, EVP Maria E. Pasquale sold 60,024 shares of the stock in a transaction on Monday, January 30th. The shares were sold at an average price of $84.74, for a total value of $5,086,433.76. Following the completion of the sale, the executive vice president now directly owns 68,524 shares of the company's stock, valued at … WebMar 9, 2024 · INCY stock opened at $73.79 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.54 and a quick ratio of 3.50. The company has a 50 day moving average price of $80.40 and a 200 day moving average price of $76.42. Incyte Co. has a fifty-two week low of $65.07 and a fifty-two week high of $86.29.
WebWith a goal to deliver medicines to patients worldwide, Incyte has expanded geographically and has operations in North America, Europe and Asia. Prior to joining Incyte, Mr. … WebApr 13, 2024 · William Blair reaffirmed an "outperform" rating on shares of Incyte in a research report on Monday, March 20th. ... The company has a quick ratio of 3.50, a current ratio of 3.54 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $75.87 and a two-hundred day moving average price of $76.89. The company has …
WebIncyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix) , … WebMar 23, 2024 · Incyte licensed retifanlimab from MacroGenics, Inc. in 2024. Shares of Incyte have lost 6.3% in the past year compared with the industry’s decline of 15.6%. Zacks …
WebStock analysis for Incyte Corp (INCY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
WebAug 2, 2024 · August 02, 2024 — 11:47 am EDT. Written by Zacks Equity Research for Zacks ->. Incyte Corporation ’s INCY earnings and revenues surpassed the Zacks Consensus Estimate in the second quarter of ... flare ups of diverticulitis symptomsWebIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is … flareup skin patchesWebFeb 7, 2024 · Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. About Jakafi® (ruxolitinib) flare ups of fop occurWebApr 5, 2024 · Incyte suffered a setback last month after the company announced that the FDA issued a complete response letter (CRL) for ruxolitinib extended-release (XR) tablets, … flare ups of hair lossWebHervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the company has tripled the number of clinical candidates in its portfolio, expanding beyond Oncology to include research and development in Inflammation & Autoimmunity. flare ups of thoracolumbar spineWebDec 31, 2024 · Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an … flare ups on searing stationcan strep throat cure itself